In general, there was a statistically significant and ~10-fold decrease in the relative size of all BLM- and CHEK2-deficient tumor spheres treated with 2ME2, ATTM and LCS-1 relative to controls (Figure 6B). This evidence concerns the gene CHEK2 and neoplasm.